Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Park EM, Deal AM, Yopp JM, Edwards T, Stephenson EM, Hailey CE, Nakamura ZM, Rosenstein DL. End-of-life parental communication priorities among bereaved fathers due to cancer. Patient Educ Couns. 2015 May;100(5):1019-23. doi: 10.1016/j.pec.2016.12.007
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Castellsague J, García-Rodríguez LA, Duque A, Perez-Gutthann S. Risk of severe cutaneous disorders in users of oral antifungals. BMC Dermatology. 2002 Nov 28;2(14). doi: 10.1186/1471-5945-2-14
Castellsague J, Garcia-Rodriuez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology. 2002;2:14.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.